Innovative adjuvant strategies for next-generation pertussis vaccines

The acellular pertussis (aP) vaccine has increasingly replaced the whole-cell pertussis (wP) vaccine due to its superior safety profile. However, the aP vaccine is less effective at preventing infection and transmission of Bordetella pertussis, highlighting the need for more effective aP vaccines. C...

Full description

Saved in:
Bibliographic Details
Main Authors: Ge Yu, Wenqi Yang, Yubin Ma, Ning Zhang, Di Tang, Ye Jin, Liang Shi, Mengshu Wang, Dawei Liu, Changying Xue, Bingbing Sun
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
Online Access:https://www.tandfonline.com/doi/10.1080/21645515.2025.2545636
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849239734621044736
author Ge Yu
Wenqi Yang
Yubin Ma
Ning Zhang
Di Tang
Ye Jin
Liang Shi
Mengshu Wang
Dawei Liu
Changying Xue
Bingbing Sun
author_facet Ge Yu
Wenqi Yang
Yubin Ma
Ning Zhang
Di Tang
Ye Jin
Liang Shi
Mengshu Wang
Dawei Liu
Changying Xue
Bingbing Sun
author_sort Ge Yu
collection DOAJ
description The acellular pertussis (aP) vaccine has increasingly replaced the whole-cell pertussis (wP) vaccine due to its superior safety profile. However, the aP vaccine is less effective at preventing infection and transmission of Bordetella pertussis, highlighting the need for more effective aP vaccines. Current aP vaccines do not elicit the robust cellular immunity necessary to eliminate intracellular bacteria and do not induce sufficient mucosal immunity to prevent bacterial colonization in the upper respiratory tract. Incorporating novel adjuvants represents a promising avenue for the future development of pertussis vaccines. Nevertheless, there remains a significant gap in understanding the application of novel adjuvants. In this article, we summarize the currently approved pertussis vaccines, focusing on the types of antigens and adjuvants used, and discuss the mechanisms of novel adjuvants. This provides valuable insights into the roles of adjuvants in pertussis vaccines, laying a foundation for designing next-generation pertussis vaccines with improved adjuvant systems.
format Article
id doaj-art-9a5da60e9a1b4acbb87bc32b6f6d06a2
institution Kabale University
issn 2164-5515
2164-554X
language English
publishDate 2025-12-01
publisher Taylor & Francis Group
record_format Article
series Human Vaccines & Immunotherapeutics
spelling doaj-art-9a5da60e9a1b4acbb87bc32b6f6d06a22025-08-20T04:00:51ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2025-12-0121110.1080/21645515.2025.2545636Innovative adjuvant strategies for next-generation pertussis vaccinesGe Yu0Wenqi Yang1Yubin Ma2Ning Zhang3Di Tang4Ye Jin5Liang Shi6Mengshu Wang7Dawei Liu8Changying Xue9Bingbing Sun10State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, ChinaState Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, ChinaState Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, ChinaState Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, ChinaState Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, ChinaSchool of Life and Health, Dalian University, Dalian, ChinaQuality System, Changchun BCHT Biotechnology Co., Changchun, ChinaQuality System, Changchun BCHT Biotechnology Co., Changchun, ChinaQuality System, Changchun BCHT Biotechnology Co., Changchun, ChinaSchool of Bioengineering, Dalian University of Technology, Dalian, ChinaState Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian, ChinaThe acellular pertussis (aP) vaccine has increasingly replaced the whole-cell pertussis (wP) vaccine due to its superior safety profile. However, the aP vaccine is less effective at preventing infection and transmission of Bordetella pertussis, highlighting the need for more effective aP vaccines. Current aP vaccines do not elicit the robust cellular immunity necessary to eliminate intracellular bacteria and do not induce sufficient mucosal immunity to prevent bacterial colonization in the upper respiratory tract. Incorporating novel adjuvants represents a promising avenue for the future development of pertussis vaccines. Nevertheless, there remains a significant gap in understanding the application of novel adjuvants. In this article, we summarize the currently approved pertussis vaccines, focusing on the types of antigens and adjuvants used, and discuss the mechanisms of novel adjuvants. This provides valuable insights into the roles of adjuvants in pertussis vaccines, laying a foundation for designing next-generation pertussis vaccines with improved adjuvant systems.https://www.tandfonline.com/doi/10.1080/21645515.2025.2545636Pertussis vaccinescombined vaccinesadjuvantsmucosal immunityformulationvaccine stability
spellingShingle Ge Yu
Wenqi Yang
Yubin Ma
Ning Zhang
Di Tang
Ye Jin
Liang Shi
Mengshu Wang
Dawei Liu
Changying Xue
Bingbing Sun
Innovative adjuvant strategies for next-generation pertussis vaccines
Human Vaccines & Immunotherapeutics
Pertussis vaccines
combined vaccines
adjuvants
mucosal immunity
formulation
vaccine stability
title Innovative adjuvant strategies for next-generation pertussis vaccines
title_full Innovative adjuvant strategies for next-generation pertussis vaccines
title_fullStr Innovative adjuvant strategies for next-generation pertussis vaccines
title_full_unstemmed Innovative adjuvant strategies for next-generation pertussis vaccines
title_short Innovative adjuvant strategies for next-generation pertussis vaccines
title_sort innovative adjuvant strategies for next generation pertussis vaccines
topic Pertussis vaccines
combined vaccines
adjuvants
mucosal immunity
formulation
vaccine stability
url https://www.tandfonline.com/doi/10.1080/21645515.2025.2545636
work_keys_str_mv AT geyu innovativeadjuvantstrategiesfornextgenerationpertussisvaccines
AT wenqiyang innovativeadjuvantstrategiesfornextgenerationpertussisvaccines
AT yubinma innovativeadjuvantstrategiesfornextgenerationpertussisvaccines
AT ningzhang innovativeadjuvantstrategiesfornextgenerationpertussisvaccines
AT ditang innovativeadjuvantstrategiesfornextgenerationpertussisvaccines
AT yejin innovativeadjuvantstrategiesfornextgenerationpertussisvaccines
AT liangshi innovativeadjuvantstrategiesfornextgenerationpertussisvaccines
AT mengshuwang innovativeadjuvantstrategiesfornextgenerationpertussisvaccines
AT daweiliu innovativeadjuvantstrategiesfornextgenerationpertussisvaccines
AT changyingxue innovativeadjuvantstrategiesfornextgenerationpertussisvaccines
AT bingbingsun innovativeadjuvantstrategiesfornextgenerationpertussisvaccines